Sign in

    Elaine Kim • H.C. Wainwright & Co.

    Elaine Kim is a Senior Equity Analyst at H.C. Wainwright & Co., specializing in healthcare and biotechnology research with a focus on emerging growth companies in the life sciences sector. She covers a diverse set of companies within biotech and pharmaceuticals, leveraging her expertise to provide incisive investment analysis and recommendations, with a notable track record reflected on platforms such as TipRanks where she maintains above-average success rates and positive returns for clients. Elaine began her career with a background in scientific research, transitioned into equity research in the early 2010s, and joined H.C. Wainwright & Co. in the late 2010s, building her credentials with prior experience at boutique investment firms. She is registered with FINRA and holds requisite securities licenses, including Series 7 and 63, and has received recognition as one of the prominent women analysts in biotech equity research.

    Elaine Kim's questions to Vaxart Inc (VXRT) leadership

    Elaine Kim's questions to Vaxart Inc (VXRT) leadership • Q2 2024

    Question

    Elaine Kim of H.C. Wainwright & Co. inquired about Vaxart's norovirus program, asking for more color on the additional information requested by the FDA and how the design of the upcoming Phase IIb trial might compare to previous studies.

    Answer

    Dr. James Cummings, Chief Medical Officer, explained that Vaxart would not disclose specific details of its ongoing discussions with the FDA, consistent with standard industry practice. He stated that the company will provide an update on the next steps for the norovirus program, including any impact on trial design, once those regulatory discussions have concluded.

    Ask Fintool Equity Research AI